Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Report - MDSpire
Advertisement
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Clinical Report: Efficacy of Survodutide in Adults with Obesity and MASLD
Overview
The SYNCHRONIZE-MASLD phase 3 trial demonstrated that survodutide significantly reduced body weight and liver fat in adults with obesity and metabolic dysfunction-related steatotic liver disease. These findings highlight the potential of survodutide as a therapeutic option for this patient population.
Background
Metabolic dysfunction-related steatotic liver disease (MASLD) is a prevalent condition associated with obesity, affecting approximately 75% of adults with obesity. Early identification and treatment are crucial to prevent disease progression to more severe forms, such as metabolic dysfunction-associated steatohepatitis (MASH), which can lead to liver fibrosis and cirrhosis. Current treatment options are limited, underscoring the need for new therapies like survodutide.
Data Highlights
Endpoint
Results
Percentage change in body weight
Significant reduction at week 48
Proportion with ≥30% reduction in liver fat content
Significant improvement at week 48
Key Findings
Survodutide treatment resulted in significant weight loss in participants with obesity.
Participants showed a ≥30% reduction in liver fat content as assessed by MRI-PDFF.
The trial included a 48-week placebo-controlled design with a dose-escalation period.
Survodutide is a dual agonist targeting glucagon and GLP-1 receptors.
Histological improvements in liver health were observed in phase 2 trials.
Clinical Implications
The findings from the SYNCHRONIZE-MASLD trial suggest that survodutide may be an effective treatment option for patients with obesity and MASLD, potentially improving both weight and liver health. Clinicians should consider this therapy as part of a comprehensive management plan for affected patients.
Conclusion
Survodutide shows promise as a novel therapeutic agent for adults with obesity and MASLD, with significant impacts on weight and liver fat reduction. Further studies will be essential to confirm these benefits and establish long-term outcomes.
by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal
